Valuation : Evolus, Inc.

Market Cap 614M 529M 497M 454M 850M 58B 852M 5.88B 2.28B 29.76B 2.31B 2.26B 95.86B P/E 2026 *
-19.2x
P/E 2027 * -59.4x
Enterprise Value 735M 633M 595M 544M 1.02B 69.42B 1.02B 7.03B 2.73B 35.62B 2.76B 2.7B 115B EV / Sales 2026 *
2.2x
EV / Sales 2027 * 1.89x
Free-Float
81.64%
Yield 2026 *
-
Yield 2027 * -
1 day+2.76%
1 week+4.73%
Current month+2.31%
1 month+25.51%
3 months+39.43%
6 months+68.17%
Current year+39.85%
1 week 8.91
Extreme 8.91
9.31
1 month 7.18
Extreme 7.18
9.31
Current year 3.86
Extreme 3.86
9.31
1 year 3.86
Extreme 3.86
9.31
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 06/05/2018
Director of Finance/CFO 48 08/09/2025
Chief Operating Officer - 01/09/2022
Director TitleAgeSince
Chairman 63 01/01/2018
Director/Board Member 71 12/02/2018
Director/Board Member 48 06/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/3/26 Sell

Chief Executive Officer

13,669 0.0211%
20/3/26 Sell

Chief Technology Officer

3,119 0.0048%
16/3/26 Exercice

Chief Technology Officer

47,604 0.0736%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%+4.73%+21.41%-4.71% 614M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.78%+0.31%+31.03%+37.89% 352B
-3.06%+2.01%+22.89%+41.87% 304B
+1.44%+1.87%+1.80%+12.58% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.16%+1.74%-14.25%-56.01% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.47%+1.61%+28.12%+46.62% 367.9B
Weighted average by Cap. -0.96%+0.62%+37.75%+67.01%

Financials

2026 *2027 *
Net sales 334M 288M 271M 247M 463M 31.57B 464M 3.2B 1.24B 16.2B 1.26B 1.23B 52.19B 391M 337M 317M 289M 542M 36.96B 543M 3.74B 1.45B 18.96B 1.47B 1.44B 61.09B
Net income -31.55M -27.15M -25.54M -23.33M -43.65M -2.98B -43.77M -302M -117M -1.53B -118M -116M -4.92B -9.69M -8.34M -7.84M -7.17M -13.41M -915M -13.44M -92.7M -35.97M -469M -36.39M -35.59M -1.51B
Net Debt 121M 104M 97.96M 89.49M 167M 11.42B 168M 1.16B 449M 5.86B 454M 444M 18.88B 126M 108M 102M 93.19M 174M 11.9B 175M 1.21B 468M 6.1B 473M 463M 19.66B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
04/09/26 USD 9.300 +2.76% 696,364
03/09/26 USD 9.050 -0.11% 734,416
02/09/26 USD 9.060 -0.22% 773,978
01/09/26 USD 9.080 -0.11% 594,023
31/08/26 USD 9.090 +2.36% 1,026,684
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.300USD
Average target price
15.00USD
Spread / Average Target
+61.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!